Literature DB >> 18191075

Body fluid abnormalities in severe hyperglycemia in patients on chronic dialysis: review of published reports.

Antonios H Tzamaloukas1, Todd S Ing, Kostas C Siamopoulos, Mark Rohrscheib, Moses S Elisaf, Dominic S C Raj, Glen H Murata.   

Abstract

Reports of dialysis-associated hyperglycemia (DH) were compared to reports of diabetic ketoacidosis (DKA) and nonketotic hyperglycemia (NKH) in patients with preserved renal function. Average serum values in DH (491 observations), DKA (1036 observations), and NKH (403 observations) were as follows, respectively: glucose, 772, 649, and 961 mg/dl; sodium, 127, 134, and 149, mmol/l; and tonicity, 298, 304, and 355 mOsm/kg. Assuming that euglycemic (serum glucose, 90 mg/dl) values were the same (sodium, 140 mmol/l; tonicity, 285 mOsm/kg) for all three states, the hyperglycemic rise in the average serum tonicity value per 100-mg/dl rise in serum glucose concentration was 1.9 mOsm/kg in DH, 3.5 mOsm/kg in DKA, and 8.1 mOsm/kg in NKH. Neurological manifestations in DH patients were caused by coexisting conditions (ketoacidosis, sepsis, and neurological disease) in most instances, and by severe hypertonicity (>320 mOsm/kg), with clearing after insulin administration, in a few instances. In 148 episodes of DH corrected with insulin only, the mean increase in serum sodium per 100-mg/dl decrease in serum glucose (Delta[Na]/Delta[Glu]) was -1.61 mmol/l. In agreement with theoretical predictions, Delta[Na]/Delta[Glu] was numerically smaller in patients with edema than in those with euvolemia. The average hyperglycemic increase in extracellular volume, calculated from changes in serum sodium concentration during correction of DH using insulin alone, was 0.013 l/l per 100-mg/dl increase in serum glucose concentration. A small number of DH patients presented with pulmonary edema rectified by insulin alone. DH causes modest hypertonicity, with few patients having neurological manifestations caused usually by other coexisting conditions. In contrast to DKA or NKH, which usually presents with hypovolemia, DH causes hypervolemia manifested occasionally by pulmonary edema. Insulin is adequate treatment for DH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18191075     DOI: 10.1016/j.jdiacomp.2007.06.012

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  16 in total

Review 1.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: a unique clinical/physiologic exercise in internal potassium balance.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-19       Impact factor: 2.370

2.  Volume depletion versus dehydration: how understanding the difference can guide therapy.

Authors:  Gautam Bhave; Eric G Neilson
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

Review 3.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-09       Impact factor: 2.370

4.  Acidosis and coma in adult diabetic maintenance dialysis patients with extreme hyperglycemia.

Authors:  Subhash Popli; Yijuan Sun; Hon-Lok Tang; Carl M Kjellstrand; Antonios H Tzamaloukas; Todd S Ing
Journal:  Int Urol Nephrol       Date:  2013-02-08       Impact factor: 2.370

Review 5.  Respiratory failure in diabetic ketoacidosis.

Authors:  Nikifor K Konstantinov; Mark Rohrscheib; Emmanuel I Agaba; Richard I Dorin; Glen H Murata; Antonios H Tzamaloukas
Journal:  World J Diabetes       Date:  2015-07-25

Review 6.  Dialysis-associated hyperglycemia: manifestations and treatment.

Authors:  Yijuan Sun; Maria-Eleni Roumelioti; Kavitha Ganta; Robert H Glew; James Gibb; Darlene Vigil; Catherine Do; Karen S Servilla; Brent Wagner; Jonathan Owen; Mark Rohrscheib; Richard I Dorin; Glen H Murata; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2020-01-18       Impact factor: 2.370

7.  Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function.

Authors:  Rodolfo J Galindo; Francisco J Pasquel; Priyathama Vellanki; Cesar Zambrano; Bonnie Albury; Citlalli Perez-Guzman; Zheng Ziduo; Guillermo E Umpierrez
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 8.  Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.

Authors:  Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 9.  Management of adult diabetic ketoacidosis.

Authors:  Aidar R Gosmanov; Elvira O Gosmanova; Erika Dillard-Cannon
Journal:  Diabetes Metab Syndr Obes       Date:  2014-06-30       Impact factor: 3.168

Review 10.  Hypertonicity: Clinical entities, manifestations and treatment.

Authors:  Helbert Rondon-Berrios; Christos Argyropoulos; Todd S Ing; Dominic S Raj; Deepak Malhotra; Emmanuel I Agaba; Mark Rohrscheib; Zeid J Khitan; Glen H Murata; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2017-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.